What was the market valuation of the UK intravenous solution market in 2024?

The market valuation of the UK intravenous solution market was $561.38 Million in 2024. Read More

What is the projected market valuation for the UK intravenous solution market by 2035?

The projected market valuation for the UK intravenous solution market is $1265.0 Million by 2035. Read More

What is the expected CAGR for the UK intravenous solution market during the forecast period 2025 - 2035?

The expected CAGR for the UK intravenous solution market during the forecast period 2025 - 2035 is 7.67%. Read More

Which companies are considered key players in the UK intravenous solution market?

Key players in the UK intravenous solution market include Baxter International Inc, B. Braun Melsungen AG, Fresenius Kabi AG, and others. Read More

What are the main segments of the UK intravenous solution market?

The main segments of the UK intravenous solution market include Nutrition Type, Bag Type, Nutritional Content, and End User. Read More

What was the valuation of the Total Parenteral Nutrition segment in 2024?

The valuation of the Total Parenteral Nutrition segment was $449.18 Million in 2024. Read More

How much is the Large Volume Bags segment projected to be worth by 2035?

The Large Volume Bags segment is projected to be worth $700.0 Million by 2035. Read More

What is the valuation range for Amino Acid Solutions in the UK intravenous solution market?

The valuation range for Amino Acid Solutions is between $80.0 Million and $180.0 Million. Read More

Which end user segment had a valuation of $336.83 Million in 2024?

The Hospital & Clinics end user segment had a valuation of $336.83 Million in 2024. Read More

What is the projected valuation for the Home Care segment by 2035?

The projected valuation for the Home Care segment is $209.3 Million by 2035. Read More

UK Intravenous Solution Market

ID: MRFR/HC/43035-HCR

200 Pages

Nidhi Mandole

Last Updated: April 06, 2026

UK Intravenous Solution Market Research Report: Size, Share, Trend Analysis By Nutrition Type (Total Parenteral Nutrition, Peripheral Parenteral Nutrition), By Bag Type (Large Volume Bags (>250 ml), Small Volume Bags (250 ml), By Nutritional Content (Amino Acid Solution, Carbohydrates, Vitamins Minerals, Parenteral Lipid Emulsion) and By End Users (Hospital Clinics, Ambulatory Surgical Centers, Home Care) - Growth Outlook & Industry Forecast 2025 To 2035

UK Intravenous Solution Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Nutrition Type (USD Million)
  1. 4.1.1 Peripheral Parenteral Nutrition
  2. 4.1.2 Total Parenteral Nutrition
2. 4.2 Construction, BY Bag Type (USD Million)
  1. 4.2.1 Large Volume Bags (>250 ml)
  2. 4.2.2 Small Volume Bags (<250 ml)
3. 4.3 Construction, BY Nutritional Content (USD Million)
  1. 4.3.1 Amino Acid Solution
  2. 4.3.2 Carbohydrates
  3. 4.3.3 Vitamins & Minerals
  4. 4.3.4 Parenteral Lipid Emulsion
  5. 4.3.5 Others
4. 4.4 Construction, BY End User (USD Million)
  1. 4.4.1 Hospital & Clinics
  2. 4.4.2 Ambulatory Surgical Centers
  3. 4.4.3 Home Care
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Baxter International Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 B. Braun Melsungen AG (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Fresenius Kabi AG (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Hospira Inc (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Terumo Corporation (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Otsuka Pharmaceutical Co Ltd (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Grifols SA (ES)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Eagle Pharmaceuticals Inc (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sagent Pharmaceuticals Inc (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY NUTRITION TYPE
3. 6.3 UK MARKET ANALYSIS BY BAG TYPE
4. 6.4 UK MARKET ANALYSIS BY NUTRITIONAL CONTENT
5. 6.5 UK MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY NUTRITION TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY NUTRITION TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY BAG TYPE, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY BAG TYPE, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY NUTRITIONAL CONTENT, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY NUTRITIONAL CONTENT, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY END USER, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY NUTRITION TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY BAG TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY NUTRITIONAL CONTENT, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Construction Market Segmentation

Construction By Nutrition Type (USD Million, 2025-2035)

Peripheral Parenteral Nutrition
Total Parenteral Nutrition

Construction By Bag Type (USD Million, 2025-2035)

Large Volume Bags (>250 ml)
Small Volume Bags (<250 ml)

Construction By Nutritional Content (USD Million, 2025-2035)

Amino Acid Solution
Carbohydrates
Vitamins & Minerals
Parenteral Lipid Emulsion
Others

Construction By End User (USD Million, 2025-2035)

Hospital & Clinics
Ambulatory Surgical Centers
Home Care

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”